U
Umberto Tirelli
Researcher at National Institutes of Health
Publications - 606
Citations - 17590
Umberto Tirelli is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lymphoma & Cancer. The author has an hindex of 67, co-authored 599 publications receiving 16899 citations. Previous affiliations of Umberto Tirelli include Nuclear Regulatory Commission & Bristol-Myers Squibb.
Papers
More filters
Journal ArticleDOI
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients.
A d'Arminio Monforte,Alessandro Cozzi Lepri,G. Rezza,Patrizio Pezzotti,Andrea Antinori,Andrew N. Phillips,G. Angarano,Vincenzo Colangeli,A. De Luca,Giuseppe Ippolito,L. Caggese,Fabrizio Soscia,Gaetano Filice,Fabrice Gritti,Pasquale Narciso,Umberto Tirelli,Mauro Moroni +16 more
TL;DR: In this paper, the authors evaluated the frequency of discontinuation of the first highly active antiretroviral regimen (HAART) and the factors predictive of discontinuing for toxicity and failure in a population-based cohort of HIV-positive individuals in Italy, naive from antirtrovirals at enrolment.
Journal ArticleDOI
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Fermé,Houchingue Eghbali,J.H. Meerwaldt,Chantal Rieux,Jacques Bosq,Françoise Berger,Theodore Girinsky,Pauline Brice,Mars B. van't Veer,Jan Walewski,Pierre Lederlin,Umberto Tirelli,Patrice Carde,Eric Van Den Neste,Emmanuel Gyan,Mathieu Monconduit,Marine Diviné,John M. M. Raemaekers,Gilles Salles,Evert M. Noordijk,Geert Jan Creemers,Jean Gabarre,Anton Hagenbeek,Oumedaly Reman,Michel Blanc,José Thomas,B. Vie,Johanna Kluin-Nelemans,Fernando Viseu,Joke W. Baars,Philip Poortmans,Pieternella J. Lugtenburg,Christian Carrie,Jérôme Jaubert,Michel Henry-Amar +34 more
TL;DR: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features and in patients with unfavorable features, four courses of chemotherapyplus involved- field radiotherapy ought to be thestandard treatment.
Journal ArticleDOI
Cancer in the elderly: why so badly treated?
I.S. Fentiman,Umberto Tirelli,S. Monfardini,M. Schneider,J. Festen,Francesco Cognetti,M.S. Aapro +6 more
Journal ArticleDOI
A multicenter study of treatment of primary CNS lymphoma
A. J. M. Ferreri,Michele Reni,F. Pasini,A. Calderoni,Umberto Tirelli,A. Pivnik,Gian Marco Aondio,F. Ferrarese,Henry L. Gomez,Maurilio Ponzoni,B. Borisch,F. Berger,C. Chassagne,Paolo Iuzzolino,Antonino Carbone,Joachim Weis,Ennio Pedrinis,T. Motta,A. Jouvet,T. Barbui,F. Cavalli,J. Y. Blay +21 more
TL;DR: Age, performance status, lactate dehydrogenase serum level, CSF protein level, site of disease, and use of HD-MTX were all predictors of survival, and combined CHT-RT is superior to RT alone.
Journal ArticleDOI
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Berthe M.P. Aleman,John M. M. Raemaekers,Umberto Tirelli,Roberto Bortolus,Mars B. van 't Veer,Marnix L.M. Lybeert,Jo J. Keuning,Patrice Carde,Theodore Girinsky,Richard W.M. van der Maazen,Radka Tomšič,Marjeta Vovk,Achilles van Hoof,Geertrui Demeestere,Pieternella J. Lugtenburg,José Thomas,Wilfried Schroyens,Koenraad De Boeck,Johanna W. Baars,Johanna Kluin-Nelemans,Christian Carrie,Malek Aoudjhane,Dominique Bron,Houchingue Eghbali,W.M. Smit,J.H. Meerwaldt,Anton Hagenbeek,Antonella Pinna,Michel Henry-Amar +28 more
TL;DR: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy, and radiotherapy may benefit patients with a partial response after chemotherapy.